Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's drug, Leqembi, and a lack of major catalysts over the next 12 months.

Needham has downgraded Biogen (BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s ...

Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...

That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...

And this corruption even extends into the Food and Drug Administration (FDA). Three years ago, Biogen got the FDA to approve its Alzheimer drug Aduhelm, even though there was little proof of its ...

Baler, Aurora, Philippines Video Recording Date/Time: November 17, 2024 at 15:35h Super Typhoon Man-Yi, known locally as Pepito, made its second landfall in Dipaculao, Aurora, at 3:20 p.m. on Sunday, ...

Alzheimer's disease—the most common form of dementia—is a progressive neurological disorder that causes brain cells to ...

(RTTNews) - UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free anti-CD40L drug candidate, showing significant clinical ...

Needham analyst Ami Fadia downgraded Biogen (BIIB) to Hold from Buy.Don't Miss our Black Friday Offers:Discover the latest stocks recommended ...

2-Year U.S. Treasury Note Continuous Contract $102.684 0.008 0.01% 5-Year U.S. Treasury Note Continuous Contract $106.680 0.016 0.01% 10-Year U.S. Treasury Note Continuous Contract $109.656 0.031 ...

Enphase Energy Inc. $61.84 2.32 3.90% ...